We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Strategies in Biomarker Research
-
1. The proteomic revolution
- Dr. Larry Gold
-
2. Lipid biomarkers: lipidomics of the macrophage and plasma lipidomes
- Prof. Edward A. Dennis
- New Tools for Biomarker Research
-
5. Development of glyco-biomarkers using glycoproteomics technologies
- Dr. Hisashi Narimatsu
-
6. Circulating nucleic acids as biomarkers in cancer patients
- Prof. Klaus Pantel
- Specific Disease Applications
-
7. Biomarkers in breast cancer
- Prof. Joe Duffy
-
8. Bacterial biomarkers
- Dr. Christiane Honisch
-
9. Diabetes biomarkers
- Prof. Naveed Sattar
-
10. Gene networks, brain networks: understanding schizophrenia
- Dr. Daniel Weinberger
-
11. Biomarkers for Huntington's disease - promises and challenges
- Prof. Sarah Tabrizi
-
12. Update on fluid biomarkers for neurodegenerative diseases
- Prof. Henrik Zetterberg
-
13. Biomarkers in osteoarthritis
- Dr. Ali Mobasheri
- Biomarkers in Drug Discovery and Delivery
-
14. Pharmacogenomics: emphasis on clinical drug development
- Dr. Amelia Warner
-
15. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Biomarkers in development, nutrition, and health
-
18. Ethnic differences in nutrition
- Prof. Jose Ordovas
-
19. Non-invasive prenatal diagnostics
- Prof. Y. M. Dennis Lo
-
20. Epigenetic biomarkers in cancer
- Prof. Bob Brown
- Archived Lectures *These may not cover the latest advances in the field
-
21. Biomarkers for Alzheimer's disease
- Prof. Henrik Zetterberg
Printable Handouts
Navigable Slide Index
- Introduction
- Alzheimer’s disease
- Neuropathological criteria for Alzheimer’s disease
- Brain changes in Alzheimer’s disease
- Molecular pathology
- Choosing the sample for biomarker analysis
- Cerebrospinal fluid (CSF)
- Is lumbar puncture dangerous?
- Core CSF biomarkers for Alzheimer’s pathology
- CSF biomarkers candidates
- Uses of biomarkers in the evaluation of patients
- CSF biomarkers for AD, Amyloid beta 42 (1)
- CSF biomarkers for AD, Amyloid beta 42 (2)
- CSF Abeta42 reflects plaque pathology (1)
- CSF Abeta42 reflects plaque pathology (2)
- Diagnostic value
- Prediction of incipient AD using CSF biomarkers
- Prediction of AD within 10 y in patients with MCI
- Sensitivity and specificity of CSF biomarkers (1)
- Sensitivity and specificity of CSF biomarkers (2)
- The Alzheimer’s Association QC program
- Can CSF markers predict development of AD? (1)
- Can CSF markers predict development of AD? (2)
- Can we measure Abeta oligomers in CSF? (1)
- Can we measure Abeta oligomers in CSF? (2)
- Are CSF biomarkers dynamic? (1)
- Are CSF biomarkers dynamic? (2)
- AD drug development
- Reference
- Biomarkers in Abeta aggregation inhibition
- Biomarkers in active Abeta immunotherapy trials
- Biomarkers in passive Abeta immunotherapy trials
- Phase III clinical trials on bapineuzumab
- The current situation in AD drug development
- Summary
- Thanks for listening
Topics Covered
- Biomarkers for Alzheimer's disease
- What is Alzheimer's disease?
- -The neuropathology of the disease -Biomarkers reflecting neuropathology
- What is CSF?
- Different uses of biomarkers
- Clinical performance of biomarkers
- Biomarkers in therapeutic trials
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Zetterberg, H. (2013, April 4). Biomarkers for Alzheimer's disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 8, 2024, from https://doi.org/10.69645/UNHG3960.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Henrik Zetterberg has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
In this talk, I will tell you about biomarkers for Alzheimer's disease.
0:06
First, I will recapitulate the key features of the disease,
in this picture you see the first patient described with the disorder.
Her name was Auguste Deter, and she was a German patient, rather young,
suffering from a progressive memory condition.
In the next picture you see Alois Alzheimer, the physician who took care of Auguste Deter at the end of her life.
He described her symptoms, and he also described
the neuropathology that he saw upon autopsy examination.
0:36
Here is a picture of what Alois Alzheimer saw in the brain of Auguste Deter.
There are three neuropathological changes that he described.
1. Senile plaques, these are dispersed throughout the brain,
they are extracellular aggregates of a protein called β-amyloid.
2. Alois Alzheimer also described neurofibrillary tangles,
which are intraneuronal protein inclusions.
3. Finally, he described general neuronal loss, and also synaptic loss.
1:07
These brain changes start to occur in the medial temporal lobe,
then they spread throughout the temporal lobe,
up through the parietal cortex, and eventually to the frontal lobe.
This correlates with the symptoms of the patient.
The first symptoms are often mild memory disturbances,
patients may be described as suffering from mild cognitive impairment.
Eventually these problems may get so severe that they fulfil dementia criteria,
that is when the memory problems are so severe that they affect daily living.
As the brain changes spread over the brain, the symptoms get worse.
Eventually, behavioral symptoms will occur, when the disease strikes the frontal lobes.
The molecular pathology of Alzheimer's disease was described in the 1980s.